Home >> Tag Archives: Boehringer Ingelheim—

Tag Archives: Boehringer Ingelheim—

FDA broadens afatinib indication

Jan. 19, 2018—Boehringer Ingelheim announced Tuesday the FDA has approved a supplemental new drug application for Gilotrif (afatinib) for the first-line treatment of patients with metastatic non-small cell lung whose tumors have nonresistant epidermal growth factor receptor mutations as detected by an FDA-approved test. The new label includes data on three additional EGFR mutations: L861Q, G719X, and S768I. The FDA ...

Read More »

Horizon, Boehringer team on oncology research, 2/13:109

Horizon Discovery has signed a research service collaboration deal with Boehringer Ingelheim to support Boehringer’s oncology programs by using Horizon’s Discovery toolbox for research projects and profiling compounds at the hit-to-lead, lead optimization, and preclinical stages to elucidate their anticancer properties and help guide drug discovery programs.

Read More »